CNQ · RVV.CN
Revive Therapeutics Ltd.
CA$0.02-CA$0.01 (-25.0%)
Revive Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.25% below the high.
Loading market information…
OTC · STHZF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
StateHouse Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
StateHouse Holdings Inc.’s next earnings report is currently expected on Dec 3, 2026, with estimated earnings per share of $0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow StateHouse Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
StateHouse Holdings Inc. operates as a vertically integrated enterprise within the U.S. cannabis sector, encompassing cultivation, processing, manufacturing, distribution, and direct retail sales of its products. The company caters to both the adult recreational and medical cannabis markets. Its retail network comprises 13 dispensaries throughout California, along with one location in Oregon, including a notable outlet situated in San Francisco's iconic Haight Ashbury district. This organization, previously known as Harborside Inc., rebranded to StateHouse Holdings Inc. in July 2022. Its corporate headquarters are located in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.08-166.67% vs estimate |
| $42.62M-34.26% vs estimate |
| Q2 2022 | Aug 26, 2022 | -$0.09-200.0% vs estimate | $44.56M-29.24% vs estimate |
|---|
| Q1 2022 | May 26, 2022 | -$0.13 | $21.61M-9.59% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.02-CA$0.01 (-25.0%)
Revive Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.25% below the high.
$0.00$0.00 (0.0%)
Ubiquitech Software Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Stella Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
A$0.01A$0.00 (0.0%)
Cann Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
$0.02-$0.01 (-20.0%)
Rafarma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.49% below the high.
$0.00+$0.00 (+50.0%)
LiveWire Ergogenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.57% below the high.
CA$0.01CA$0.00 (0.0%)
Pharmadrug Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Resilient Healthcare Corp’s quoted price sits in the lower half of its reported 52-week range, 92.98% below the high.
